Dr. Lal PathLabs Beheer

Beheer criteriumcontroles 2/4

De CEO Dr. Lal PathLabs is Shankha Banerjee, benoemd in May2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.028% van de aandelen van het bedrijf, ter waarde ₹ 67.09M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 5.8 jaar.

Belangrijke informatie

Shankha Banerjee

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking

Jan 16

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jan 01

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Oct 26

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Oct 24

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

Oct 06

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31

CEO

Shankha Banerjee

less than a year

Tenure

Mr. Shankha Banerjee serves as Chief Executive Officer of Group & Associates Companies at Dr. Lal PathLabs Limited. He served as Chief Operating Officer at Dr. Lal PathLabs Limited since 2020. He had been...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Arvind Lal	Executive Chairman	29.9yrs	₹30.14m	32.93% ₹ 78.3b
Om Manchanda	MD & Director	4.8yrs	₹46.45m	1.01% ₹ 2.4b
Vandana Lal	Executive Director	no data	₹24.18m	19.3% ₹ 45.9b
Shankha Banerjee	Chief Executive Officer	less than a year	geen gegevens	0.028% ₹ 67.1m
Ved Goel	Group CFO & CEO of International Business	6.4yrs	₹7.30m	0.014% ₹ 34.4m
Jai Meena	Chief Operating Officer	2.8yrs	geen gegevens	geen gegevens
Munender Soperna	Chief Information & Digital Officer	10.6yrs	geen gegevens	0.025% ₹ 59.7m
Vinay Gujral	Company Secretary & Compliance Officer	1.8yrs	geen gegevens	0% ₹ 0
Manoj Garg	Group Chief Human Resources Officer	10.3yrs	geen gegevens	0.033% ₹ 77.6m

4.8yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LALPATHLAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Arvind Lal	Executive Chairman	29.9yrs	₹30.14m	32.93% ₹ 78.3b
Om Manchanda	MD & Director	13.9yrs	₹46.45m	1.01% ₹ 2.4b
Vandana Lal	Executive Director	29.9yrs	₹24.18m	19.3% ₹ 45.9b
Arun Duggal	Lead Independent Director	1.9yrs	₹3.85m	geen gegevens
Rajit Mehta	Independent Director	1.5yrs	₹1.56m	geen gegevens
Rahul Sharma	Non Executive Director	19.5yrs	₹2.65m	0.026% ₹ 61.3m
Rohit Bhasin	Independent Non-Executive Director	2.2yrs	₹2.60m	geen gegevens
Somya Satsangi	Independent Director	5.9yrs	₹2.70m	geen gegevens
Archana Erdmann	Non-Executive Director	5.7yrs	₹2.25m	1.85% ₹ 4.4b
Gurinder Singh Kalra	Independent Director	1.5yrs	₹1.56m	geen gegevens

5.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LALPATHLAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/01/31 20:48
Aandelenkoers aan het einde van de dag	2025/01/31 00:00
Inkomsten	2024/12/31
Jaarlijkse inkomsten	2024/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Dr. Lal PathLabs Limited wordt gevolgd door 46 analisten. 22 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Prashant Nair	Ambit Capital
Nitin Bhasin	Ambit Capital
null null	Antique Stockbroking Ltd.

Dr. Lal PathLabs Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Non Executive Director recently sold ₹15m worth of stock

MD & Director recently sold ₹79m worth of stock

MD & Director recently sold ₹35m worth of stock

Company Secretary & Compliance Officer recently sold ₹1.7m worth of stock

Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025

MD & Director recently sold ₹28m worth of stock

Recent updates

Third quarter 2025 earnings: EPS misses analyst expectations

Dr. Lal Pathlabs Limited Approves Declaration Third Interim Dividend for Financial Year 2024-25

Dr. Lal PathLabs Limited to Report Q3, 2025 Results on Jan 30, 2025

Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking

Non Executive Director recently sold ₹15m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

MD & Director recently sold ₹79m worth of stock

MD & Director recently sold ₹35m worth of stock

Company Secretary & Compliance Officer recently sold ₹1.7m worth of stock

Upcoming dividend of ₹6.00 per share

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025

Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

MD & Director recently sold ₹28m worth of stock

Price target increased by 12% to ₹2,924

First quarter 2025 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs Limited Approves Interim Dividend for the Fiscal Year 2024-25

Dr. Lal PathLabs Limited to Report Q1, 2025 Results on Aug 07, 2024

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Non Executive Director recently sold ₹14m worth of stock

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

Upcoming dividend of ₹6.00 per share

MD & Director recently sold ₹29m worth of stock

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

MD & Director recently sold ₹36m worth of stock

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Non Executive Director recently sold ₹7.8m worth of stock

Price target increased by 8.0% to ₹2,353

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023

Dr. Lal PathLabs Limited Announces Change in Directorate

Dr. Lal PathLabs Limited Announces Change in Directorate

MD & Director recently sold ₹32m worth of stock

Upcoming dividend of ₹12.00 per share at 0.5% yield

Price target increased by 7.2% to ₹2,091

Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023

Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023)

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

MD & Director recently sold ₹41m worth of stock

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹43m worth of stock